166. Pseudoxanthoma elasticum
11 clinical trials,   23 drugs   (DrugBank: 6 drugs),   5 drug target genes,   26 drug target pathways

Searched query = "Pseudoxanthoma elasticum", "PXE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04441671
(ClinicalTrials.gov)
December 8, 202020/1/2020Oral Pyrophosphate Absorption in PXE DiseaseOral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumDrug: Disodium PyrophosphateTampere University HospitalUMC Utrecht;Hungarian Academy of SciencesNot yet recruiting18 Years80 YearsAll12Phase 2NULL
2NCT04660461
(ClinicalTrials.gov)
February 4, 20203/12/2020Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum)Drug: Lansoprazole 30mg;Drug: PlaceboFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludNULLRecruiting18 YearsN/AAll20Phase 4Spain
3EUCTR2016-004021-16-ES
(EUCTR)
31/10/201810/03/2017Response to oral lansoprazole in patients with Pseudoxanthoma ElasticumResponse to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg disease (Pseudoxanthoma Elasticum) - FIM-PXE-2016-01 Grönblad-Stranberg disease (Pseudoxanthoma Elasticum)
MedDRA version: 19.1;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: Lansoprazole
INN or Proposed INN: Lansolprazole
Other descriptive name: LANSOPRAZOLE
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 2Spain
4EUCTR2018-001492-20-FI
(EUCTR)
20/06/201811/06/2018Pyrophosphate therapy in PXE diseasePseudoxanthoma elasticum – supplementation therapy of pyrophosphate deficiency Pseudoxanthoma elasticum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SODIUM ACID PYROPHOSPHATE
Product Name: SODIUM ACID PYROPHOSPHATE SAPP ROR 28 FOOD GRADE
Product Code: CAS No.: 7758-16-9
Tampere university hospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 2;Phase 3Finland
5NCT02537054
(ClinicalTrials.gov)
September 201521/8/2015Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumDrug: AfliberceptUniversity Hospital, BonnNULLCompleted18 Years65 YearsAll15Phase 2Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2014-005263-33-DE
(EUCTR)
29/04/201526/02/2015Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticumIntravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNeP Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum
MedDRA version: 20.0;Level: PT;Classification code 10037150;Term: Pseudoxanthoma elasticum;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: EyleaMedizinische Fakultät der Universität BonnNULLNot RecruitingFemale: yes
Male: yes
15Phase 2Germany
7EUCTR2013-001421-55-FR
(EUCTR)
13/06/201322/09/2015An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSEAn open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSE Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Retinal Vein Occlusion (RVO) or Diabetic macular edema (DME) and other ocular neovascularization and/or complication such as Rubeosis Iridis and Neovacular Glaucoma and Proliferative Diabetic Retinopathy requiring Vitrectomy
MedDRA version: 18.0;Level: HLGT;Classification code 10047060;Term: Retina, choroid and vitreous haemorrhages and vascular disorders;System Organ Class: 10015919 - Eye disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: Lucentis
Product Name: Lucentis
Product Code: RFB002A
INN or Proposed INN: RANIBIZUMAB
Novartis Pharma S.A.SNULLNot RecruitingFemale: yes
Male: yes
500Phase 3France
8NCT01525875
(ClinicalTrials.gov)
August 20121/2/2012Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumDrug: Magnesium Oxide;Drug: PlaceboMark LebwohlNULLCompleted18 YearsN/AAll44Phase 2United States
9NCT00510965
(ClinicalTrials.gov)
August 20071/8/2007Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)Ranibizumab in Choroidal Neovascularization (CNV) Due to Pseudoxanthoma Elasticum (PXE, Groenblad-Strandberg-Syndrome)Choroidal NeovascularizationDrug: Intravitreal injection ranibizumabUniversity Hospital, BonnNovartisCompleted18 Years65 YearsBoth10Phase 2Germany
10EUCTR2006-006231-49-DE
(EUCTR)
24/07/200706/03/2007Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06 Pseudoxanthoma elasticum (PXE) is an inherited systemic disease characterized by changes in the elastic tissue. Pseudoxanthoma elasticum mainly affects the skin, eyes, heart, and GI system. The cutaneous and ocular findings of PXE are referred to as Grönblad-Strandberg syndrome. Pseudoxanthoma elasticum may be autosomal dominant or autosomal recessive. In Pseudoxanthoma elasticum, choroidal nevoscualrization (CNV) is a frequently occuring complication in late stage disease
MedDRA version: 8.1;Level: LLT;Classification code 10037150;Term: Pseudoxanthoma elasticum
Trade Name: Lucentis
Product Name: Lucentis
Product Code: RFB002
INN or Proposed INN: ranibizumab
Other descriptive name: RFB002, rhuFab V2
Department of Ophthalmology, Bonn UniversityNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00470977
(ClinicalTrials.gov)
May 20074/5/2007Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related MaculopathyTreatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection)Coats' Disease;Idiopathic Retinal Telangiectasia;Retinal Angiomatous Proliferation;Polypoidal Choroidal Vasculopathy;Pseudoxanthoma Elasticum;Pathological Myopia;Multi-focal Choroiditis;Rubeosis Iridis;Von Hippel Lindau Disease;BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)Drug: ranibizumab injection (0.5 mg)Manhattan Eye, Ear & Throat HospitalGenentech, Inc.Completed18 YearsN/ABoth18Phase 1;Phase 2United States